Chronic Lymphocytic Leukemia PBMC

About Chronic Lymphocytic Leukemia PBMC

Chronic Lymphocytic Leukemia PBMC for Leukemia Research

Chronic Lymphocytic Leukemia (CLL) PBMC products are sourced from IRB-consented donors clinically diagnosed with CLL and processed within 24 hours of collection under standardised conditions. CLL is unique among the leukemias in that the malignant clone circulates in large numbers in peripheral blood, often accounting for the majority of circulating lymphocytes at diagnosis. This makes PBMCs an especially disease-relevant, non-invasive source of both leukemic and residual normal immune cells for downstream study.

CLL Biology and Why Peripheral Blood

• CLL is characterised by clonal accumulation of mature-appearing, functionally incompetent B lymphocytes that co-express CD5 and CD19/CD20, typically in numbers high enough to make peripheral blood diagnostic on its own via flow cytometry.
• IGHV mutation status and cytogenetic abnormalities detected by FISH – including del(17p), del(11q), trisomy 12 and del(13q) – are the key prognostic and predictive markers routinely assessed from peripheral blood.
• The proportion of circulating clonal cells makes PBMCs efficient for bulk and single-cell studies of the leukemic clone without the need for marrow aspiration.
• Peripheral T cell and NK cell compartments in CLL show well-documented dysfunction, including T cell exhaustion and skewed subset ratios, positioning PBMCs as a useful matrix for immune dysfunction research alongside the leukemic clone itself.
• Targeted therapies including BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax) have driven demand for peripheral blood-derived material in pharmacodynamic, resistance, and minimal residual disease research.

Donor Stratification Available

• IGHV mutation status where documented
• Cytogenetic abnormalities by FISH, including del(17p), del(11q), trisomy 12 and del(13q)
• Disease stage (Rai/Binet) and treatment history
• Prior or current BTK inhibitor/BCL-2 inhibitor exposure where reported
• Age band and sex assigned at birth
• Matched healthy donor PBMCs available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed CLL donors
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• Custom aliquot sizes available on request
• IRB-approved protocols and electronic informed consent

De-identified Donor Data

• Verified CLL diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Disease stage and treatment history where documented
• Additional CLL-specific data available upon request

Applications

• Immunophenotyping of the clonal B-cell population and residual T/NK compartments by flow cytometry
• Bulk and single-cell RNA sequencing of leukemic and non-leukemic peripheral immune populations
• IGHV and cytogenetic prognostic marker studies
• BTK inhibitor and BCL-2 inhibitor pharmacodynamic and resistance research
• Minimal residual disease assay development
• T cell exhaustion and immune dysfunction studies in CLL
• Biomarker discovery and drug screening in patient-derived cells

Other Chronic Lymphocytic Leukemia Specimen Types

• Chronic Lymphocytic Leukemia (CLL) Bone Marrow Mononuclear Cells

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11 – compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Chronic Lymphocytic Leukemia PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse donor cohorts across our full inventory, visit our human PBMCs page.